[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"VASCage GmbH\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":198},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,68,113,144,172],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100652810","chip-in-health-and-disease-100652810",false,"NCT07780552","CHIP in Health and Disease","DECONVOLUTION OF CLONAL HEMATOPOIESIS ASSOCIATED INFLAMMATION IN HEALTH AND DISEASE","CHIP2","Inclusion Criteria: Participants must be ≥18 years of age and meet at least one of the following criteria:\n\n* Written informed consent has been obtained for participation in the study \"Deconvolution of Clonal Hematopoiesis-Associated Inflammation in Health and Disease\"; OR\n* Participant is enrolled in the Inn.Health study and has provided written informed consent; OR\n* Participant is enrolled in the study \"Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction\" and has provided written informed consent.\n\nGroup A: Control Group (n=20)\n\n* Age ≥60 years\n* No detectable somatic variant identified by peripheral blood next-generation sequencing (NGS)\n* No history of stroke or myocardial infarction\n* No surgery within the previous 3 months\n* No diagnosis of a WHO-defined neoplasm\n* No cytopenia at study enrollment Group B: Low-Risk Clonal Hematopoiesis Risk Score (CHRS) Group (n=20)\n* Age ≥60 years\n* Somatic variant in DNMT3A, TET2, ASXL1, or JAK2 with variant allele frequency (VAF) ≥2% in peripheral blood\n* No history of stroke or myocardial infarction\n* No surgery within the previous 3 months\n* No diagnosis of a WHO-defined neoplasm\n* No cytopenia at study enrollment\n* Low-risk CHRS (\\\u003C9.5 points) Group C: Intermediate-\u002FHigh-Risk CHRS Group (n=20)\n* Age ≥60 years\n* Somatic variant in DNMT3A, TET2, ASXL1, or JAK2 with VAF ≥2% in peripheral blood\n* No history of stroke or myocardial infarction\n* No surgery within the previous 3 months\n* No diagnosis of a WHO-defined neoplasm\n* No cytopenia at study enrollment\n* Intermediate- or high-risk CHRS (\\>9.5 points) Group D: Clonal Cytopenia of Undetermined Significance (CCUS) Group (n=20)\n* Age ≥60 years\n* Somatic variant in DNMT3A, TET2, ASXL1, or JAK2 with VAF ≥2% in peripheral blood\n* No history of stroke or myocardial infarction\n* No surgery within the previous 3 months\n* No diagnosis of a WHO-defined neoplasm\n* Untreated, unexplained cytopenia present for ≥4 months\n* Hemoglobin \\\u003C13 g\u002FdL (men) or \\\u003C12 g\u002FdL (women), and\u002For absolute neutrophil count \\\u003C1.8 × 10⁹\u002FL, and\u002For platelet count \\\u003C150 × 10⁹\u002FL\n* No diagnostic criteria for a defined myeloid neoplasm based on bone marrow examination Group E: Cardiovascular Disease Group (n=20)\n* Age ≥60 years\n* Somatic variant in DNMT3A, TET2, ASXL1, or JAK2 with VAF ≥2% in peripheral blood\n* ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI) within the previous 4 months\n* No history of coronary artery bypass grafting (CABG)\n* No history of stroke\n* No cytopenia at study enrollment\n* No diagnosis of a WHO-defined neoplasm Group F: Low-Risk Myelodysplastic Syndrome (MDS) Group (n=20)\n* Age ≥60 years\n* Untreated, newly diagnosed (\\\u003C3 months from diagnosis) low-risk myelodysplastic syndrome according to the Revised International Prognostic Scoring System (IPSS-R score \\>1.5 to 3.0)\n* No history of stroke or myocardial infarction\n\nExclusion Criteria:\n\n* Treatment with immunosuppressive medication within the previous 4 weeks, including but not limited to systemic corticosteroids, methotrexate, other disease-modifying antirheumatic drugs (DMARDs), colchicine, TNF-α inhibitors, mTOR inhibitors, calcineurin inhibitors, or immunomodulatory antibodies\n* History of rheumatologic, autoinflammatory, or autoimmune disease",true,"ALL","18 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), is an age-associated condition characterized by the expansion of hematopoietic stem and progenitor cell clones carrying acquired somatic mutations. Although CH is associated with an increased risk of hematologic malignancies, its greater public health impact derives from its strong association with cardiovascular diseases, including coronary artery disease and stroke. Emerging evidence suggests that CH-associated mutations promote chronic inflammatory signaling in myeloid immune cells, thereby contributing to atherosclerosis and adverse cardiovascular remodeling.\n\nThis observational translational study aims to characterize the biological spectrum of clonal hematopoiesis across different stages of disease risk and manifestation. Using state-of-the-art single-cell and multi-omics approaches, the study will compare inflammatory pathways, immune cell states, and mutation-associated molecular programs among healthy individuals without CH, individuals with high-risk CH, and patients with CH-associated hematologic or cardiovascular disease. The ultimate goal is to identify shared and disease-specific mechanisms linking clonal hematopoiesis to adverse clinical outcomes and to generate insights for future preventive, anti-clonal, and anti-inflammatory therapeutic strategies.",[26,27,28,29,30,31,32],"Clonal Hematopoiesis","Clonal Hematopoiesis of Indeterminate Potential","Clonal Cytopenia of Undetermined Significance (CCUS)","Myelodysplastic Syndrome","Cardiovascular Disease","Myocardial Infarction (MI)","ST-elevation Myocardial Infarction (STEMI)",[26,34,35,36,37,38,39,40,30,41,42,43,28,44,45,46,47,48,49,50,51,52,53,54],"Clonal Hematopoiesis of Indeterminate Potential (CHIP)","Somatic Mutations","DNMT3A","TET2","ASXL1","Inflammation","Myeloid Cells","Atherosclerosis","Myocardial Infarction","STEMI","Myelodysplastic Syndromes (MDS)","Single-Cell RNA Sequencing","Multi-Omics","Immune Profiling","NLRP3 Inflammasome","cGAS-STING Pathway","Precision Medicine","Cardiovascular Risk","Healthy Aging","Chronic Inflammation","Biomarkers","NOT_YET_RECRUITING","2026-08-18",{"date":58,"type":59},"2026-08-21","ACTUAL",{"date":61,"type":22},"2026-10",{"date":63,"type":22},"2027-03",{"name":65,"class":66},"VASCage GmbH","OTHER",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":88,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":67},"100649623","predication-of-arterial-stiffness-in-healthy-adults-by-oral-health-and-chewing-assessments-100649623","NCT07736222","Predication of Arterial Stiffness in Healthy Adults by Oral Health and Chewing Assessments","Oral Structural and Functional Profile as an Additive Biomarker for Explaining Central Arterial Stiffness in the INN.HEALTH Cohort","INNoralHEALTH","Inclusion Criteria:\n\n* adults meeting the INN.HEALTH cohort eligibility criteria, including age ≥18 years, residence in Innsbruck City or Innsbruck-Land, and capacity to consent\n* additionally at Visit 4, participants must report being able to safely chew and, where required, swallow the standardized test materials\n\nExclusion Criteria:\n\n* temporalmandibular joint disorders\n* severe jaw joint complaints\n* active dental treatment at the time of assessment\n* inability to safely chew\u002Fswallow the standardized test materials.",{"count":77,"type":22},750,"INTERVENTIONAL",[80],"NA","INN.oral.HEALTH is an sub-study embedded in the Innsbruck Health Promotion Program (INN.HEALTH). The study investigates whether oral health, oral structure, and oral function provide additional information for understanding vascular health in adults from the general population.\n\nCardiovascular and cerebrovascular diseases, such as heart attack and stroke, remain major causes of death and disability. Many risk factors, including blood pressure, blood lipids, blood sugar, smoking, physical activity, sleep, and diet, are already known to influence vascular health. However, oral health may also be related to vascular risk. Conditions such as tooth loss, impaired chewing, reduced tongue strength, or oral disease burden may reflect or contribute to general health and vascular ageing, but their additional value in prevention programs is not yet well understood.\n\nThe main hypothesis of this study is that a standardized oral structure and function profile can improve the explanation of central arterial stiffness beyond established cardiovascular risk factors and lifestyle-related health metrics (INN.HEALTH study). Central arterial stiffness will be assessed using carotid-femoral pulse wave velocity, a marker of vascular ageing and cardiovascular risk.\n\nParticipants will undergo a single oral assessment during Visit 4 of the INN.HEALTH study. The assessment includes screening of oral health status, dentition, bite force, tongue pressure, chewing efficiency, chewing and swallowing performance, questionnaires on oral health-related quality of life and food avoidance, and measurement of masseter muscle thickness. The study does not involve any treatment.\n\nThe results may help clarify whether oral structural and functional markers can contribute to future vascular risk assessment and prevention strategies in the general adult population.",[83,84,85,86,87,51],"Arterial Stiffness","Oral Health","Mastication","Deglutition","Vascular Aging",[89,90,91,92,93,94,95,85,96,97,98,99,100,101,102,103],"Carotid-femoral pulse wave velocity","Pulse wave velocity","Central arterial stiffness","Oral health","Bite force","Tongue pressure","Chewing efficiency","Swallowing","Test of Masticating and Swallowing Solids","ToMASS","Food avoidance","Oral health-related quality of life","Masseter muscle thickness","Life's Essential 8","Vascular prevention","RECRUITING","2026-07-27",{"date":107,"type":59},"2026-07-30",{"date":109,"type":59},"2026-07-08",{"date":111,"type":22},"2027-03-31",{"name":65,"class":66},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":78,"phases":123,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100632298","digital-application-for-stroke-health-100632298","NCT07511868","Digital Application for Stroke Health","Evaluating a Digital Health Application for Post-stroke Care and Vascular Risk Factor Management - a Multicenter Randomized Controlled Clinical Investigation","DASH","Inclusion Criteria:\n\n1. Male or female patient (biological sex) ≥18 years at the time of consent\n2. Hospitalization for acute ischemic stroke, acute haemorrhagic stroke or TIA\n3. Necessary Technical Equipment (smartphone or tablet computer) and skills\n4. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Cerebral infarction due to cerebral venous thrombosis (CVT)\n2. Severe Psychiatric Conditions\n3. Severe pre-existing cognitive impairment\n4. Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) or other patients where salt restriction is harmful.\n5. Inability to operate the device independently (assistance from a caregiver is acceptable). E.g.:\n\n   * Severe apraxia,\n   * Severe Motor Disabilities,\n   * Severe Visual Impairment\n   * Severe Communication Barriers (e.g. Severe Aphasia, Severe Dysarthria)\n6. Inability to speak and read German to a level which allows fully comprehending the meaning of everything that is said and written.\n7. Women of childbearing potential not willing to adopt effective contraceptive measures during the clinical investigation\n8. Patients who are considered to be part of the vulnerable population:\n\n   * Persons unable to give consent\n   * Minors\n   * Persons performing military service\n   * persons detained by court or official order or accommodated in accordance with the Accommodation Act, Federal Law Gazette No. 155\u002F1990\n   * Pregnant or breastfeeding women",{"count":122,"type":22},500,[80],"Stroke is a leading cause of death and long-term disability worldwide. Despite substantial advances in acute stroke care, there remains a lack of evidence-based digital solutions to support patients after hospital discharge. This study evaluates the effectiveness of a digital health application (StrokeApp) designed to support patients with ischemic or hemorrhagic stroke or transient ischemic attack (TIA) in secondary prevention and recovery.\n\nIn this multicenter, randomized, controlled, open-label trial, 500 patients will be assigned in a 1:1 ratio to receive either standard care alone or standard care in combination with StrokeApp. The primary objective is to assess the impact of the application on health-related quality of life three months after discharge. Secondary and exploratory outcomes include health literacy, medication adherence, vascular risk factors, health-related behaviors, psychosocial outcomes, long-term recovery up to twelve months, as well as safety and user experience.",[126,127,128],"Haemorrhagic Stroke","Ischaemic Stroke","Transient Ischemic Attack (TIA)",[130,131,132,133,134],"Digital Health Application","Post Stroke","Medical Device","App","stroke aftercare","2026-03-30",{"date":137,"type":59},"2026-04-06",{"date":139,"type":22},"2026-04-01",{"date":141,"type":22},"2026-12-31",{"name":65,"class":66},7,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":78,"phases":154,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":67},"100588379","exploratory-study-on-the-potential-cross-system-effects-of-bci-fes-hand-therapy-on-dysphagia-and-aphasia-in-chronic-stroke-patients-100588379","NCT06940635","Exploratory Study on the Potential Cross-System Effects of BCI-FES Hand Therapy on Dysphagia and Aphasia in Chronic Stroke Patients","Cross-Stroke Therapy Effects With BCI and FES Stimulation: A Pilot Study","c-STEPS","Inclusion Criteria:\n\n* Age: Participants must be aged 18 years or older.\n* Post-Stroke Phase: Participants must be within the chronic post-stroke phase (time since ischemic or haemorrhagic stroke greater than 3 months).\n* Motor Impairment: Participants must exhibit disabling left or right residual arm paresis (\"left\u002Fright arm motor drift\" part of the NIHSS score ≥1).\n* Speech\u002FSwallowing Impairment: Participants must have:\n\n  * Aphasia (AAT-Skala zum Kommunikationsverhalten score ≤3), and\u002For\n  * Dysphagia (MUCCS-N score ≥2).\n* Stable Neurological Status: No relevant changes in neurological status in the past 4 weeks (self-reported).\n* Motor Function: Participants must be able to raise at least 1 block similar to the ones in Box-and-Block-Test.\n* Cognitive Understanding: Participants must be able to understand basic spoken instructions.\n* Sitting Tolerance: Participants must be able to maintain a sitting position for at least 60 minutes.\n* Willingness to Participate: Participants must be willing to participate in the study and able to understand and sign the informed consent.\n\nExclusion Criteria:\n\n* Cognitive Impairments: Cognitive impairments that, in the investigator's judgment, could limit understanding of task instructions.\n* Stroke Location: Participants with a brainstem and\u002For cerebellar stroke.\n* Previous Stroke: Participants with a previous disabling stroke.\n* Hemi-Neglect: Pronounced hemi-neglect at the last documented therapy visit that limits compliance with treatment intervention (investigator's judgment).\n* Anosognosia: Pronounced anosognosia at the last documented therapy visit that limits compliance with treatment intervention (investigator's judgment).\n* Spasticity: Severe spasticity in the affected limb, resulting in complete rigidity in flexion or extension.\n* Seizure Disorders: Participants with uncontrolled epilepsy (investigator's judgement) or epileptic seizure within the last month.\n* Intracranial Pressure: Known ongoing elevated intracranial pressure.\n* Implanted Medical Devices: Participants with implanted medical devices with contraindication for FES such as pacemakers.\n* Metallic Fragments: Participants with implanted metallic fragments in the extremity planned for FES that would limit the use of functional electrical stimulation (FES).\n* Unhealed Injuries: Unrecovered fractures or skin\u002Ftissue lesions in the FES stimulated extremity.\n* Joint Issues: Ossification, contraction, or stiffness of the wrist joint in the FES stimulated extremity that would limit treatment.\n* Botulinum Toxin: Participants who received botulinum-toxin treatment within 6 weeks prior to study inclusion and\u002For for whom botulinum-toxin treatment is planned during the study duration.\n* Co-morbidities: The following conditions will exclude participation:\n\n  * Chronic Obstructive Pulmonary Disease (Stage IV).\n  * Cardiac insufficiency (NYHA Stage IV).\n  * Severe acute infections.\n  * Significant circulatory disturbances in the stimulated extremity.\n  * Sensory disorders that significantly impair the patient's ability to feel pain or react to unsuitable proprioceptive stimuli.\n  * Any other general medical conditions that, in the investigator's judgment, limit the safety or performance of study procedures (investigator's judgement).\n* Electrical Stimulation Intolerance: Known inability to tolerate cutaneous electrical stimulation.",{"count":153,"type":22},10,[80],"The goal of this neurorehabilitation explorative study is to investigate how a closed-loop Brain-Computer Interface Functional Electrical Stimulation (BCI-FES) therapy, used within the intended purpose for hand rehabilitation, may impact swallowing difficulties (dysphagia) and language disorders (aphasia) in post-stroke patients.",[127,157],"Hemorrhagic Stroke",[159,160,161,162,163],"neurorehabilitation","BCI-FES","chronic stroke","aphasia","dysphagia","2025-11-25",{"date":166,"type":59},"2025-11-26",{"date":168,"type":59},"2025-06-04",{"date":170,"type":22},"2026-06-30",{"name":65,"class":66},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":78,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":197,"locationsCount":67},"100578621","innsbruck-health-promotion-program-100578621","NCT06813677","Innsbruck Health Promotion Program","INNHEALTH","Inclusion Criteria:\n\n* Signed informed consent of subject\n* Main area of residence in Innsbruck and Innsbruck-Land\n\nExclusion Criteria:\n\n* People who are suspended upon a court order or upon other legal processes or are accommodated according ot the Hospitalization Act, or for whom a custodian is appointed (or appointment is inititated)\n* Persons with impaired power of judgement\n* Persons who are currently engaged in military or community service",{"count":180,"type":22},1000,[80],"The primary goal of this single-centre. single-arm, unblinded, pre-post interventional study is to evaluate whether a one-time health assessment and intervention affects the overall vascular health evaluated through the Life's Essential 8 overall vascular health score.\n\nSecondary goals of this study are, among others:\n\n* to describe incidence and prevalence of vascular risk-factors and behaviours\n* to explore prevalence and associations of health and disease in the general population with special focus on cardiovascular risk, cardiovascular diseases, markers of vascular health, signs and (prodromal) symptoms of neurodegeneration as well as psychosocial factors\n* to explore the prevalence of hearing disorders in the general population\n* to collect voice and speech samples to identify novel biomarkers that correlate to vascular health and\u002For hearing status",[184],"Assessment of Vascular Health Risk Factors",[102,186,187,188,189,190],"PBMC","Cardiovascular health","Quality of Life","Mitochondrial function","Hearing impairment","2025-11-18",{"date":193,"type":59},"2025-11-19",{"date":195,"type":59},"2025-05-01",{"date":111,"type":22},{"name":65,"class":66},""]